Dulera Metered-Dose Inhalation Aerosol

Dulera's Pressurized Aerosol Format Shapes the Decision

Dulera is a pressurized metered-dose inhalation aerosol containing mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist. The practical distinction is its device: unlike a breath-activated dry powder inhaler, Dulera must be shaken, and each actuation has to be coordinated with a slow, deep breath. That difference can matter as much as the ingredients when choosing between maintenance inhalers.

We list one strength: 5 mcg of formoterol fumarate plus 200 mcg of mometasone furoate per actuation. We offer order quantities of 2, 4, or 6 inhalers, so the catalogue choice concerns the number of inhalers rather than a choice between strengths. The prescribed number of actuations and treatment schedule should still come from the clinician managing the asthma plan.

Dulera is intended for regular asthma maintenance, not the treatment of a sudden attack. A reader considering it should therefore assess three separate points: whether this ingredient combination is appropriate, whether a pressurized aerosol device suits their inhalation technique, and whether the listed strength matches the prescription or clinical instructions they have received.

What Is Dulera and Where Does It Fit in Asthma Care?

Dulera belongs to the inhaled corticosteroid and long-acting beta2-agonist class of combination medicines. Mometasone helps control airway inflammation, while formoterol relaxes the smooth muscle surrounding the airways. Combining them in one inhaler allows both components to be taken as part of the same scheduled maintenance routine.

A clinician may consider this type of combination when an inhaled corticosteroid alone has not provided adequate control or when the person's asthma warrants treatment with both components. It is not automatically preferable to every corticosteroid-only or combination inhaler. Previous response to treatment, symptom pattern, exacerbation history, device technique, age, other medical conditions, and the approved treatment plan all influence the choice.

The usual labelled routine involves regular morning and evening use, exactly as prescribed. Dulera must not be substituted for a fast-acting reliever during acute symptoms. A person whose prescribed reliever is becoming less effective, who needs it more often than usual, or whose breathing is deteriorating should seek medical advice promptly rather than taking extra Dulera actuations unless specifically instructed to do so.

Who May Consider Dulera, and Which Factors Matter?

Dulera may be discussed for adults and adolescents aged 12 years and older who need combination maintenance treatment for asthma. Its safety and effectiveness have not been established for children younger than 12 years. For adolescents using an inhaled corticosteroid over time, clinicians generally monitor growth as part of routine follow-up.

Important points to discuss with a prescriber or pharmacist include:

• Current asthma control: worsening symptoms, nighttime waking, activity limitations, or increasing reliever use may indicate that the treatment plan needs reassessment.
• Inhaler technique: a pressurized aerosol requires coordination between pressing the canister and inhaling. A clinician or pharmacist can check technique and determine whether an appropriate spacer should be considered.
• Diabetes: formoterol can increase blood glucose in some people, so additional monitoring may be advisable.
• Heart or circulation conditions: beta2-agonists can cause palpitations, changes in heart rate, tremor, or effects on blood pressure and should be used cautiously when relevant cardiovascular conditions are present.
• Pregnancy or breastfeeding: available evidence is limited, so a healthcare professional should assess the expected benefit and possible risk before treatment is started, stopped, or changed.
• Allergies: the relevant restriction is known hypersensitivity to mometasone furoate, formoterol fumarate, or another product ingredient, rather than an unspecified history of allergies.

These factors do not determine suitability on their own. They help a clinician decide whether the medicine, strength, device, and routine are appropriate for a particular person.

Two Ingredients With Complementary Roles

Mometasone furoate reduces inflammation in the airway lining. This can lower airway sensitivity and support steadier control when the medicine is used consistently. Because inflammation can persist even when symptoms are quiet, the corticosteroid component is taken regularly rather than only when wheezing or shortness of breath is noticeable.

Formoterol fumarate is a long-acting bronchodilator. It relaxes airway smooth muscle and helps keep the airways more open between scheduled doses. Some bronchodilation may begin relatively soon after an administered dose, but that does not make Dulera an acute rescue medicine. The product is not indicated for treating an asthma attack, and its combination maintenance role must be distinguished from the role of a prescribed fast-acting reliever.

Taking both components in one device can simplify a regimen compared with using two separate maintenance inhalers. That convenience only helps when the inhaler is used correctly and consistently. Missed doses, poor coordination, an empty canister, or stopping treatment when symptoms temporarily improve can all reduce control.

A Reliable Inhalation Routine

Correct technique is essential for a metered-dose inhalation aerosol. Follow the product instructions and any demonstration provided by a healthcare professional. The usual sequence includes:

1. Remove the cap, inspect the mouthpiece, and make sure it is clear.
2. Shake the inhaler well before each actuation.
3. Prime it before first use and reprime it if it has not been used for more than five days, following the product instructions.
4. Breathe out fully away from the mouthpiece. Do not breathe into the device.
5. Seal your lips around the mouthpiece, begin a slow and deep inhalation through the mouth, and press the canister once.
6. Continue breathing in, then hold your breath for as long as is comfortable before breathing out slowly.
7. If another actuation has been prescribed, wait and repeat the instructed sequence.
8. After the complete dose, rinse your mouth with water and spit it out without swallowing. This helps reduce oral thrush and hoarseness associated with inhaled corticosteroids.

The inhaler should be stored at 20°C to 25°C; excursions between 15°C and 30°C are permitted. Store it with the mouthpiece facing down. Because the contents are under pressure, do not puncture or incinerate the canister, and do not expose it to temperatures above 48.9°C.

Ask a healthcare professional to recheck technique if doses seem inconsistent, medicine appears to collect in the mouth, or pressing and inhaling together is difficult. Technique problems should be addressed before assuming that the active ingredients are ineffective.

One Strength With Three Order Quantities

We list Dulera only as a metered-dose inhalation aerosol delivering 5 mcg of formoterol fumarate plus 200 mcg of mometasone furoate per actuation. The available order quantities are 2, 4, and 6 inhalers. These quantities do not change the active ingredients, strength, route, or dosage form.

The appropriate quantity depends on the prescribed routine, the intended treatment period, and whether continued use has already been confirmed by the treating clinician. Check the exact product name and strength against the prescription or treatment instructions before ordering. Do not estimate how long an order will last without also checking the prescribed number of actuations and the labelled number of doses in each supplied inhaler.

A larger quantity may reduce the frequency of repeat ordering for an established regimen, but it is not inherently a better choice. A person beginning a new medicine or changing devices should first make sure that the selected product and technique have been clinically confirmed.

What Results and Timing Are Realistic?

Dulera is intended to improve ongoing asthma control when used consistently. Formoterol can begin relaxing airway smooth muscle relatively quickly, while the full anti-inflammatory benefit of mometasone develops with regular use. The time needed to achieve stable control varies, and a response to an early dose should not be interpreted as permission to use Dulera as a rescue inhaler.

Useful treatment outcomes can include fewer daytime or nighttime symptoms, less disruption of activity, reduced reliance on a fast-acting reliever, and fewer exacerbations. These outcomes are assessed over time rather than guaranteed after a specific number of doses. Keeping track of symptoms, reliever use, nighttime waking, and any written peak-flow instructions can help a clinician evaluate whether the maintenance plan is working.

Do not stop Dulera abruptly merely because breathing feels better. Improved symptoms may reflect successful control from regular treatment. Any planned reduction, switch, or discontinuation should be discussed with the prescriber. Conversely, worsening wheeze, chest tightness, breathlessness, or declining response to the reliever requires prompt assessment.

Safety Priorities During Treatment

Dulera is not intended to treat acute bronchospasm or an asthma attack. Follow the written asthma action plan and use the prescribed reliever for sudden symptoms. Seek urgent medical help when severe breathing difficulty develops, symptoms worsen rapidly, or the reliever does not provide the expected response.

Common or clinically important concerns associated with inhaled corticosteroid and beta2-agonist treatment include oral thrush, hoarseness, throat irritation, headache, tremor, nervousness, palpitations, and muscle cramps. Rinsing the mouth after the full dose and maintaining good inhaler hygiene can reduce some local corticosteroid effects.

Stop using the inhaler and obtain urgent medical advice if an actuation immediately causes increased wheezing or breathing difficulty, which may indicate paradoxical bronchospasm. Immediate care is also appropriate for signs of a serious allergic reaction, such as swelling of the face or throat, widespread hives, or difficulty breathing.

Long-term or high corticosteroid exposure can have systemic effects, although inhaled treatment is designed to act mainly in the lungs. Clinicians may consider bone health, eye conditions such as glaucoma or cataracts, adrenal effects, infection risk, and growth in adolescents when these issues are relevant. Use only the prescribed dose and do not add another long-acting beta2-agonist medicine.

Interactions and Practical Precautions

Provide the prescriber and pharmacist with a complete list of prescription medicines, non-prescription products, and supplements. Relevant interactions or precautions can include:

• Other long-acting beta2-agonists: using another medicine from this class with Dulera can increase adverse effects without providing an appropriate additional benefit.
• Beta-blockers: these medicines can reduce the effect of formoterol and may provoke bronchospasm in susceptible people. A clinician should assess the need and selectivity of beta-blocker treatment.
• Potassium-lowering diuretics: concurrent use may increase the risk of low blood potassium, particularly when beta2-agonist exposure is high.
• Strong CYP3A4 inhibitors: medicines such as ketoconazole, itraconazole, or ritonavir can increase systemic exposure to mometasone and may require closer assessment.
• Monoamine oxidase inhibitors and tricyclic antidepressants: these may intensify cardiovascular effects associated with formoterol.
• Medicines that affect heart rhythm: additional caution may be needed when another treatment can prolong the QT interval or otherwise increase the risk of an abnormal rhythm.

Formoterol can cause dizziness, tremor, palpitations, nervousness, or headache, particularly when treatment begins or more medicine than prescribed is taken. Until the individual response is known, use caution with driving or tasks requiring full concentration if these effects occur.

How Does Dulera Compare With Other Combination Inhalers?

Comparisons should begin with ingredients, device type, dosing schedule, available strengths, and the person's ability to use the device correctly. Dulera combines mometasone with formoterol in a pressurized aerosol. Other inhaled corticosteroid and long-acting bronchodilator combinations use different corticosteroids, different bronchodilators, dry powder devices, pressurized devices, or different dosing schedules.

Symbicort combines budesonide with formoterol. It shares the formoterol component with Dulera, but the corticosteroid differs, and the device must be checked for the specific marketed presentation. This may be relevant when someone has previously responded well to budesonide or has a strong preference for a particular device.

Advair Diskus combines fluticasone propionate with salmeterol in a breath-activated dry powder inhaler. It avoids the press-and-breathe coordination required by Dulera, but a dry powder device requires an adequate, forceful inhalation and has its own technique. Breo Ellipta combines fluticasone furoate with vilanterol and is generally used on a once-daily schedule, which may suit someone prioritizing fewer scheduled dosing times. Its ingredients and device are different, so it is not a direct strength-for-strength substitute.

No option is universally best. A suitable choice depends on the approved indication, prescribed strength, previous response, side effects, inhalation ability, and the dosing routine a person can follow reliably. Our Asthma category provides access to related catalogue options, but a brand or device change should be confirmed by a prescriber or pharmacist.

Canadian Brand and Prescription Context

Health Canada lists the mometasone furoate and formoterol fumarate combination under the Canadian brand Zenhale. That authorization does not by itself establish Dulera as an authorized Canadian brand. The shared active ingredients should not obscure the need to verify the exact brand, strength, device, labelling, and market identity.

Authorized mometasone and formoterol inhalers in Canada, including Zenhale, are prescription medicines. Our ordering process does not require customers to submit a prescription, but that operational policy does not change the medicine's Canadian prescription classification or replace assessment by a licensed healthcare professional. A customer in Canada should confirm that Dulera is the exact product intended by the prescriber rather than assuming that brand names are interchangeable.

Suspected adverse reactions can be reported to Health Canada through the Canada Vigilance program. Urgent symptoms should be assessed through appropriate emergency or clinical services rather than handled only as a product-order question.

Ordering Options and Support

We have supported customers since 2017. Our support team is available 24/7 by email, online chat, and phone, and pharmacist support is available for product-related questions. Catalogue prices are presented in Canadian dollars.

Before ordering, compare the displayed product name, metered-dose aerosol form, oral inhalation route, and 5 mcg formoterol fumarate plus 200 mcg mometasone furoate strength with the treatment instructions. We offer quantities of 2, 4, or 6 inhalers. Select the quantity only after considering the prescribed schedule and whether ongoing use of this exact product has been confirmed.

Support can clarify catalogue identity and available order quantities, but it should not be used to self-select a maintenance medicine or alter a dose. Questions about suitability, switching from another inhaler, acute symptoms, or changes to an asthma action plan belong with the treating prescriber or another qualified healthcare professional.

A Focused Final Decision

Dulera is a reasonable product to discuss when a prescribed asthma plan calls for mometasone furoate and formoterol fumarate in a pressurized metered-dose inhalation aerosol. Its main practical advantages are delivery of both maintenance components through one device and a consistent scheduled routine. Its main decision points are the need for coordinated aerosol technique, the single listed strength, twice-daily use as directed, and its status as a maintenance rather than rescue inhaler.

Before placing an order, confirm the exact brand and market identity, verify the 5 mcg plus 200 mcg per-actuation strength, make sure the device can be used correctly, and review relevant cautions and interactions. If those points align with the prescribed plan, the remaining catalogue decision is whether 2, 4, or 6 inhalers represent an appropriate quantity for the established routine.